Artigo de periodico

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) (2023)

• Authors:
  • Bonifácio, Lívia Pimenta - Universidade de São Paulo (USP)
  • Ramacciotti, Eduardo
  • Agati, Leandro Barile
  • Vilar, Fernando Crivelenti
  • Silva, Anna Christina Tojal da
  • Louzada Junior, Paulo
  • Fonseca, Benedito Antonio Lopes da
  • Souza, Hayala Cristina Cavenague de
  • Oliveira, Caroline Candida Carvalho de
  • Aguiar, Valeria Cristina Resende
  • Kallas, Esper Georges
  • Rodrigues, Fernando Bellíssimo
• USP affiliated authors: RODRIGUES, FERNANDO BELLISSIMO - FMRP ; KALLAS, ESPER GEORGES - FM
• Unidades: FMRP; FM
• DOI: 10.1590/0037-8682-0565-2022
• Subjects: COVID-19; PACIENTES INTERNADOS; PANDEMIAS; BRASIL
• Agências de fomento:
  • Financiamento CNPq
  • Financiamento MCTI
• Language: Inglês
• Imprenta:
  • Publisher place: Brasilia
  • Date published: 2023
• Source:
  • Título do periódico: Revista da sociedade brasileira de medicina tropical
  • ISSN: 0037-8682
  • Volume/Número/Paginação/Ano: v. 56, article ID e0565-2022, 10p, 2023

Informações sobre o DOI: 10.1590/0037-8682-0565-2022 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: gold
• Licença: cc-by

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  BONIFÁCIO, Lívia Pimenta et al. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, v. 56, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54695. Acesso em: 03 jun. 2024.

• APA

  Bonifácio, L. P., Ramacciotti, E., Agati, L. B., Vilar, F. C., Silva, A. C. T. da, Louzada Junior, P., et al. (2023). Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, 56. doi:10.1590/0037-8682-0565-2022

• NLM

  Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 jun. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695

• Vancouver

  Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 jun. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors)
• Lower numbers of natural killer T cells in HIV-1 and mycobacterium leprae co-infected patients
• No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis
• Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
• Streamlining HIV Testing for HIV Preexposure Prophylaxis
• The Abbott Pandemic Defense Coalition: a unique multisector approach adds to global pandemic preparedness efforts
• HLA-C downregulation by HIV-1 adapts to host HLA genotype
• Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance
• Antigenic competition in CD4(+) T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
• Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial